Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named

Adaptive Biotechnologies Corp

Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.
MRD revenue ~$31-32M, up ~47% YoY; Immune Medicine revenue implied by difference.
Strategic review concludes: run MRD and Immune Medicine internally with separate resources and segment reporting.
CFO Tycho Peterson departs; Kyle Piskel (Principal Accounting Officer, 8-yr tenure) appointed full-time CFO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Adaptive Biotechnologies Corp reported first quarter ended March 31, 2024 results: revenue approximately $41 to $43 million.

Period: first quarter ended March 31, 2024
Revenue: approximately $41 to $43 million
Result: preliminary results

Exact text from the filing

process and outcome of the strategic review during the conference call this afternoon. First Quarter 2024 Preliminary Unaudited Revenue Results • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023. • MRD revenue of approximately $31 to $32 million for the

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0000950170-24-042291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.